Opdivo (Nivolumab) Dosing: Not Based on Body Surface Area
Opdivo is NOT dosed based on body surface area (BSA). The FDA-approved dosing regimens use either weight-based dosing (mg/kg) or flat fixed dosing (mg), but never BSA-based dosing (mg/m²) 1.
FDA-Approved Dosing Options
The current FDA label provides three distinct dosing strategies for nivolumab monotherapy 1:
- Weight-based dosing: 3 mg/kg every 2 weeks
- Flat dosing: 240 mg every 2 weeks OR 480 mg every 4 weeks
When used in combination with ipilimumab, the options include 1:
- Weight-based: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for 4 doses, followed by nivolumab 3 mg/kg every 2 weeks
- Hybrid approach: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for 4 doses, followed by nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks
Clinical Practice Dosing
Current ASCO guidelines consistently reference these same dosing strategies across multiple melanoma treatment settings 2:
- 240 mg IV every 2 weeks
- 480 mg IV every 4 weeks
- 3 mg/kg IV every 2 weeks (when used in certain combinations)
The NCCN guidelines similarly support the "flip-dose" regimen of nivolumab 3 mg/kg + ipilimumab 1 mg/kg for neoadjuvant therapy, demonstrating reduced toxicity while maintaining efficacy 3.
Important Dosing Considerations
Volume restrictions apply for preparation 1:
- Adults and pediatric patients ≥40 kg: maximum 160 mL total infusion volume
- Pediatric patients <40 kg: maximum 4 mL/kg body weight
The shift from weight-based to flat dosing was supported by pharmacokinetic modeling showing that flat dosing reduces drug wastage without compromising exposure or efficacy 4. However, some jurisdictions have adopted hybrid strategies combining weight-based and flat dosing for patients with lower body weights to avoid unnecessarily high doses 5.
Dose-response analyses demonstrated that nivolumab monotherapy at 3 mg/kg every 2 weeks provides adequate receptor saturation and clinical benefit across tumor types, with a plateau in response rates at doses ≥3 mg/kg 6.
Common Pitfall to Avoid
Do not confuse nivolumab dosing with other immunotherapy agents. While some monoclonal antibodies use BSA-based dosing (as seen with farletuzumab ecteribulin at 33 mg/m² 7), nivolumab specifically uses weight-based or flat dosing only. Using BSA calculations for nivolumab would be incorrect and not supported by any regulatory approval or clinical guideline.